PRESS RELEASE   Biotest AG increases sales by 6% in financial year 2024 EBIT guidance of € 94.5 million at the upper end of the forecast range achieved Marketing authorization application for fibrinogen submitted in key European markets and to the US Food and Drug Administration (FDA) Approval of Yimmugo in June 2024 by the US Food and D [ … ]

PRESS RELEASE   Important milestone for Biotest: Biologics License Application for Fibrinogen submitted to the US Food and Drug Administration (FDA)   Biotest's fibrinogen aims to fulfill a high unmet medical need for additional fibrinogen to treat acquired fibrinogen deficiency US submission follows EU application for marketing authorizatio [ … ]